Close Menu


The company will continue to evaluate several agents, including its c-MET inhibitor APL-101 for patients with a variety of MET dysregulated solid cancers.

Instead of trying to tackle resistance by targeting rare mutations, researchers are looking to antibody based therapies that are more broadly active in lung cancer patients.